Evidence map›Paper›PMID 41436461›Full record

ArticleNPJ vaccines2025

Intranasal vaccination with probiotic Escherichia coli membrane vesicles displaying pneumococcal capsular polysaccharides elicits mucosal immunity.

Ryoma Nakao, Soichiro Kimura, Kimihiro Abe, Takehiro Yamaguchi, Eisuke Kuroda, Shigeto Hamaguchi, Kazuhiro Tateda, Yukino Ohki, Naoki Narisawa, Makoto Ohnishi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ryoma NakaoDepartment of Bacteriology I, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), Shinjuku-ku, Tokyo, Japan. nakao.ry@jihs.go.jp.ORCID http://orcid.org/0000-0002-4802-8518
Soichiro KimuraDivision of Infection Prevention and Control, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Yokohama, Kanagawa, Japan.
Kimihiro AbeDepartment of Bacteriology I, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), Shinjuku-ku, Tokyo, Japan.
Takehiro YamaguchiDepartment of Bacteriology I, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), Shinjuku-ku, Tokyo, Japan.
Eisuke KurodaDepartment of Transformative Analysis for Human Specimen, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Shigeto HamaguchiDepartment of Transformative Analysis for Human Specimen, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Kazuhiro TatedaDepartment of Microbiology and Infectious Diseases, Faculty of Medicine, Toho University School of Medicine, Ota-ku, Tokyo, Japan.
Yukino OhkiDepartment of Food Bioscience and Biotechnology, College of Bioresource Science, Nihon University; 1866, Kameino, Fujisawa, Kanagawa, Japan.
Naoki NarisawaDepartment of Food Bioscience and Biotechnology, College of Bioresource Science, Nihon University; 1866, Kameino, Fujisawa, Kanagawa, Japan.
Makoto OhnishiDepartment of Bacteriology I, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), Shinjuku-ku, Tokyo, Japan.
Yukihiro AkedaDepartment of Bacteriology I, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), Shinjuku-ku, Tokyo, Japan.

Funding

Japan Agency for Medical Research and Development JP18fk0108124Japan Society for the Promotion of Science 19K22644Japan Society for the Promotion of Science (KAKENHI) 20H03861Japan Society for the Promotion of Science (KAKENHI) 22K08609
6 · The paper itself

Abstract

A novel vaccine modality is needed to generate both systemic and mucosal immunity in the respiratory tract, where pathogens are most likely to colonize and to initiate infection. Here, we demonstrated that intranasal immunization with probiotic Escherichia coli-derived membrane vesicles displaying serotype-14 pneumococcal capsule (CPS14

Identifiers

PMID41436461
PMCPMC12830806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.